Flygt, H, Söderlund, S, Stentoft, J, Richter, J, Koskenvesa, P, Mustjoki, S, Majeed, W, Lübking, A, Dreimane, A, Markevärn, B, Stenke, L, Myhr Eriksson, K, Gjertsen, B T, Gedde-Dahl, T, Dimitrijevic, A, Udby, L, Olsson-Strömberg, U & Hjorth-Hansen, H 2021, ' Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study ', European Journal of Haematology, vol. 107, no. 6, pp. 617-623 . https://doi.org/10.1111/ejh.13699 Flygt, H, Söderlund, S, Stentoft, J, Richter, J, Koskenvesa, P, Mustjoki, S, Majeed, W, Lübking, A, Dreimane, A, Markevärn, B, Stenke, L, Myhr Eriksson, K, Gjertsen, B T, Gedde-Dahl, T, Dimitrijevic, A, Udby, L, Olsson-Strömberg, U & Hjorth-Hansen, H 2021, ' Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study ', European journal of haematology, vol. 107, no. 6, pp. 617-623 . https://doi.org/10.1111/ejh.13699
for the Nordic CML Study Group (NCMLSG) 2016, ' Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients ', Leukemia, vol. 30, no. 9, pp. 1853-1860 . https://doi.org/10.1038/leu.2016.121